GMAB vs INCY
Genmab A/S and Incyte, both Healthcare
Incyte is the larger company at $20B against $16B. Over the past year INCY returned +65% against +49% for GMAB. Ryufin's sector-relative Smart Score puts INCY ahead, 10/10 against 9/10.
| Figure | GMAB | INCY |
|---|---|---|
| Last close | $33.75 | $128 |
| Market cap | $16B | $20B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 18.1 |
| 1-year return | +49% | +65% |
| 5-year return | -25% | +66% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.